[go: up one dir, main page]

BRPI0409405A - compostos 7-aza-quinazolina substituìdos - Google Patents

compostos 7-aza-quinazolina substituìdos

Info

Publication number
BRPI0409405A
BRPI0409405A BRPI0409405-0A BRPI0409405A BRPI0409405A BR PI0409405 A BRPI0409405 A BR PI0409405A BR PI0409405 A BRPI0409405 A BR PI0409405A BR PI0409405 A BRPI0409405 A BR PI0409405A
Authority
BR
Brazil
Prior art keywords
aza
substituted
quinazoline compounds
compounds
quinazoline
Prior art date
Application number
BRPI0409405-0A
Other languages
English (en)
Inventor
Nolan James Dewdney
David Michael Goldstein
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BRPI0409405A publication Critical patent/BRPI0409405A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"COMPOSTOS 7-AZA-QUINAZOLINA SUBSTITUìDOS". A presente invenção refere-se a compostos de Fórmula (I) ou (II) onde R, R6, R7 e Q são como indicados no relatório descritivo. Os compostos são de utilidade como inibidores de p38 quinase, podendo ser usados no tratamento de distúrbio mediado por p38.
BRPI0409405-0A 2003-04-16 2004-04-13 compostos 7-aza-quinazolina substituìdos BRPI0409405A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46322903P 2003-04-16 2003-04-16
PCT/EP2004/003883 WO2004091625A1 (en) 2003-04-16 2004-04-13 (6-(phenoxy)-pyrido`3,4-d! pyrimidin-2-yl)-amine derivatives as p38 kinase inhibitors for the treatment of inflammatoryy conditions such as rheumatois artritis

Publications (1)

Publication Number Publication Date
BRPI0409405A true BRPI0409405A (pt) 2006-04-25

Family

ID=33300055

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0409405-0A BRPI0409405A (pt) 2003-04-16 2004-04-13 compostos 7-aza-quinazolina substituìdos

Country Status (16)

Country Link
US (2) US7189731B2 (pt)
EP (1) EP1620105B1 (pt)
JP (1) JP2006523640A (pt)
KR (1) KR20060006037A (pt)
CN (1) CN1774250A (pt)
AR (1) AR044515A1 (pt)
AU (1) AU2004229163A1 (pt)
BR (1) BRPI0409405A (pt)
CA (1) CA2520785A1 (pt)
CL (1) CL2004000805A1 (pt)
DE (1) DE602004004259T2 (pt)
ES (1) ES2279361T3 (pt)
MX (1) MXPA05010975A (pt)
RU (1) RU2005135329A (pt)
TW (1) TW200503722A (pt)
WO (1) WO2004091625A1 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004020908A1 (de) * 2004-04-28 2005-11-17 Grünenthal GmbH Substituierte 5,6,7,8,-Tetrahydro-pyrido[4,3-d]pyrimidin-2-yl- und 5,6,7,8,-Tetrahydro-chinazolin-2-yl-Verbindungen
US20090131430A1 (en) * 2004-11-23 2009-05-21 Palle Venkata P Pyrido'2,3-dipyrimidines as anti-inflammatory agents
RU2293560C2 (ru) * 2005-03-09 2007-02-20 Лидия Николаевна Долгова Способ лечения хронических гонартритов у больных остеоартрозом
RU2293559C2 (ru) * 2005-03-09 2007-02-20 Лидия Николаевна Долгова Способ подготовки к любрикантной терапии
ES2303758B1 (es) * 2006-02-20 2009-08-13 Laboratorios Almirall S.A. Nuevos derivados de piridin-3-amina.
EP1992344A1 (en) 2007-05-18 2008-11-19 Institut Curie P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation
WO2010104406A1 (en) 2009-03-11 2010-09-16 Auckland Uniservices Limited Prodrug forms of kinase inhibitors and their use in therapy
MX336332B (es) * 2009-09-02 2016-01-15 Auckland Uniservices Ltd Inhibidores de cinasa, formas de profarmaco de los mismos y su uso en terapia.
US20190060286A1 (en) 2016-02-29 2019-02-28 University Of Florida Research Foundation, Incorpo Chemotherapeutic Methods
EP3691620B1 (en) 2017-10-05 2022-07-27 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce dux4 and downstream gene expression for the treatment of fshd
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1199768A (en) 1966-10-31 1970-07-22 Pfizer & Co C Nitrogen Heterocycles and process for their preparation
JPS4936700A (pt) * 1972-08-16 1974-04-05
US4672116A (en) 1985-12-20 1987-06-09 Ortho Pharmaceutical Corporation Substituted 5,6-dialkoxyquinazoline derivatives
US5084463A (en) 1989-12-11 1992-01-28 American Home Products Corporation N-quinolinyl alkyl-substituted 1-aryloxy-2-propanolamine and propylamine derivatives possessing class III antiarrhythmic activity
US20020061879A1 (en) 1996-02-02 2002-05-23 Garvey David S. Nitrosated and nitrosylated alpha-adrenergic receptor antagonist compounds, compositions and their uses
WO1998038984A2 (en) 1997-03-05 1998-09-11 Sugen, Inc. Formulations for hydrophobic pharmaceutical agents
US6313294B1 (en) 1998-02-04 2001-11-06 Development Center For Biotechnology Process for preparing amides
AU1071301A (en) 1999-11-01 2001-05-14 Eli Lilly And Company Pharmaceutical compounds
CA2386955A1 (en) 1999-11-22 2001-05-31 Warner-Lambert Company Quinazolines and their use for inhibiting cyclin-dependent kinase enzymes
EP1110552A1 (en) 1999-12-22 2001-06-27 Aventis Pharma S.A. Use of a compound with affinity for the mitochondrial benzodiazepine receptor in cancer therapy
US6605615B2 (en) 2000-03-01 2003-08-12 Tularik Inc. Hydrazones and analogs as cholesterol lowering agents
HUP0300721A3 (en) 2000-07-26 2006-02-28 Smithkline Beecham Plc Aminopiperidine quinolines and their azaisosteric analogues with antibacterial activity, process for producing them, pharmaceutical compositions containing them and use thereof
AUPR213700A0 (en) 2000-12-18 2001-01-25 Biota Scientific Management Pty Ltd Antiviral agents
DE60206363T2 (de) * 2001-02-12 2006-07-06 F. Hoffmann-La Roche Ag 6-substituierte pyridopyrimidine
DE60231868D1 (de) 2001-04-24 2009-05-20 Purdue Research Foundation Folat-mimetika und deren folatrezeptorbindende konjugate
WO2002090360A1 (en) * 2001-05-10 2002-11-14 Smithkline Beecham Corporation Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
MXPA05001332A (es) * 2002-08-06 2005-04-28 Hoffmann La Roche 6-alcoxi-pirido-pirimidinas como inhibidores de cinasa del map p-38.

Also Published As

Publication number Publication date
US20040209903A1 (en) 2004-10-21
WO2004091625A1 (en) 2004-10-28
MXPA05010975A (es) 2005-11-28
TW200503722A (en) 2005-02-01
DE602004004259T2 (de) 2007-11-15
EP1620105A1 (en) 2006-02-01
CN1774250A (zh) 2006-05-17
RU2005135329A (ru) 2006-08-10
ES2279361T3 (es) 2007-08-16
US7189731B2 (en) 2007-03-13
CL2004000805A1 (es) 2005-02-04
AU2004229163A1 (en) 2004-10-28
DE602004004259D1 (de) 2007-02-22
US20070135459A1 (en) 2007-06-14
EP1620105B1 (en) 2007-01-10
AR044515A1 (es) 2005-09-14
CA2520785A1 (en) 2004-10-28
KR20060006037A (ko) 2006-01-18
JP2006523640A (ja) 2006-10-19

Similar Documents

Publication Publication Date Title
DE60315146D1 (de) Heteroarylsubstituierte biphenylderivate als inhibitoren von p38-kinase
ATE517896T1 (de) P38-kinase-inhibitoren
HRP20050228A2 (en) Novel phenanthridines
DE602005009318D1 (de) Kondensierte heteroyralderivate zur verwendung als p38-kinase-inhibitoren
ATE551059T1 (de) Fasudil in kombination mit bosentan zur behandlung von pulmonaler arterieller hypertonie
ATE556713T1 (de) Omega-carboxyarylsubstituierte-diphenyl- harnstoffe als p38-kinasehemmer
BR0112965A (pt) Derivados de 3-indolil-4-fenil-1h-pirrol-2,5-diona como inibidores de glocogênio sintase cinase-3beta
BRPI0409580A (pt) compostos de quinazolina
DE60117605D1 (de) Thiazolyl-inhibitoren von tyrosinkinasen der tec-familie
CY1110965T1 (el) Επιπροσθετες ετεροπολυκυκλικες ενωσεις και η χρηση τους ως ανταγωνιστες μεταβολοτροπικου υποδοχεα γλουταμικου
ATE348616T1 (de) 2-hydroxy-6-phenylphenanthridine als pde-4-hemmer
ATE353217T1 (de) 3-hydroxy-6-phenylphenanthridine als pde-4 inhibitoren
DE60214703D1 (de) Thiazolverbindungen, die sich als inhibitoren von proteinkinasen eignen
CY1112947T1 (el) Παραγωγα πυρρολης καταλληλα για την θεραπεια πολλαπλασιαστικων ασθενειων
ATE381539T1 (de) Dipeptidylpeptidase-hemmer zur behandlung von diabetes
BR0215360A (pt) Derivados de indolina úteis como inibidores de proteìna quinase
ES2249309T3 (es) Compuestos de 3,4-dihidro-(1h)quinazolin-2-ona como inhibidores de csbp/p39 kinasa.
ATE429228T1 (de) Derivate von piperazine-2-carboxamide
DK1483251T3 (da) C3-cyano-epothilon-derivater
BRPI0409405A (pt) compostos 7-aza-quinazolina substituìdos
BRPI0416030A (pt) pirido-7-pirimidin-7-onas substituìdas com hidroxialquila
ATE413392T1 (de) Kondensierte heteroyralderivate und deren verwendung als p38-kinase-inhibitoren
DK1406893T3 (da) Bicykliske pyrrolidinforbindelser
BRPI0407913A (pt) antagonistas receptores de ccr-3
DK1362045T3 (da) 2-Thio-substituerede imidazolderivater og deres anvendelse inden for farmacien

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired